Pharmafile Logo
Pharmafocus logo
Advanced Search

Eisai

Showing 15 posts of 114 posts found.

Eisai image

Eisai and Novartis part ways

January 8, 2013
Sales and Marketing COPD, Eisai, Novartis, Onbrez, Spiriva

Novartis and Eisai have abandoned their co-promotion agreement for three of Novartis’ chronic obstructive pulmonary disease treatments. The move follows …

News

Pharma manufacturing news in brief

December 21, 2012
Manufacturing and Production Amarin, BASF, Bioden Idec, Eisai, Lonza, Patheon, Sartorious Stedim Biotech, banner pharmacaps

BASF extends offer for ProNova, Patheon closes Banner Pharmacaps deal, plus updates from Amarin, Biogen Idec/Eisai and Lonza.

News
Eisai image

SMC first to give Fycompa thumbs-up

December 12, 2012
Sales and Marketing Eisai, Fycompa, SMC, Scotland, epilepsy

The Scottish Medicines Consortium (SMC) has approved Eisai’s first-in-class epilepsy drug Fycompa for use in the NHS in Scotland – …

News
Eisai image

Eisai opens Fycompa UK manufacturing line

September 25, 2012
Manufacturing and Production, Sales and Marketing Eisai, Fycompa

Eisai has opened a new solid dose production line for epilepsy drug Fycompa at its UK base in Hatfield, Hertfordshire. …

News
Halaven image

UK at centre of Eisai plans

September 18, 2012
Research and Development, Sales and Marketing CNS, Cancer Drugs Fund, Eisai, Fycompa, Halaven

Diseases of the central nervous system (CNS) and cancer will be the main areas targeted by Japanese firm Eisai as …

News
Eisai image

Eisai launches epilepsy drug in UK

September 14, 2012
Sales and Marketing Eisai, UK, epilepsy

Eisai has launched its first-in-class epilepsy drug Fycompa in the UK, prior to a roll-out in EU member states including …

News
FDA image

FDA clears Arena and Eisai’s obesity drug

June 28, 2012
Sales and Marketing Arena, Belviq, Eisai, FDA, Qnexa, Roche, obesity

Eisai and Arena’s Belviq has gained FDA approval, making it the first obesity drug to be approved in over ten …

News

Eisai to enter Russia with epilepsy launch

June 27, 2012
Sales and Marketing Eisai, Russia, Zonegran, emerging markets, epilepsy

Eisai is to enter the Russian market for the first time with the launch of epilepsy drug Zonegran. Entry into the …

News

Recommendations for two Eisai epilepsy drugs

May 28, 2012
Sales and Marketing CHMP, Eisai, Zonegra, epilepsy

European regulators are likely to approve two of Eisai’s epilepsy drugs after advisers recommended both of them.First-in-class Fycompa (perampanel) has …

News
FDA picture

Obesity drugs vie for approval as FDA panel backs lorcaserin

May 14, 2012
Research and Development, Sales and Marketing Arena, Eisai, FDA, Qnexa, lorcaserin, obesity

An FDA panel has recommended Arena’s obesity drug lorcaserin, setting up a showdown with Vivus’ Qnexa. Qnexa was recommended by an FDA panel …

News
Halaven image

NICE rejects Halaven for breast cancer

April 3, 2012
Sales and Marketing Eisai, Halaven, NICE, breast cancer

NICE has rejected Eisai’s novel breast cancer drug Halaven, due to concerns over its safety and costs.  In its final …

News
Eisai logo

Eisai expands UK base

March 21, 2012
Sales and Marketing EMEA, Eisai, Hatfield, expansion

Eisai is expanding its UK headquarters to support the company’s growing European, Middle Eastern and African business. The expansion will …

News

Takeda’s blood pressure treatment Edarbi approved

December 9, 2011
Sales and Marketing Diovan, Eisai, cardiovascular, high blood pressure, hypertension

Takeda’s new hypertension treatment Edarbi has been approved in Europe.Edarbi (azilsartan medoxomil) is a new once-daily angiotensin receptor blocker (ARB) …

News

NICE will not back Eisai’s Halaven

November 17, 2011
Medical Communications, Sales and Marketing Eisai, Halaven, NICE, breast cancer

NICE has not recommended Eisai’s novel breast cancer drug Halaven due to concerns over its safety and cost.In draft guidance …

News

Eisai shares risk with novel trial funding approach

September 7, 2011
Research and Development Eisai, clinical trials, research and development news

Eisai has unveiled a novel risk-sharing approach to accelerate its late-stage research programme by accepting new sources of clinical trial …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025